ME02557B - Fuzionisani biciklicni oksazoliidinon kao inhibitor cetp - Google Patents

Fuzionisani biciklicni oksazoliidinon kao inhibitor cetp

Info

Publication number
ME02557B
ME02557B MEP-2016-268A MEP2016268A ME02557B ME 02557 B ME02557 B ME 02557B ME P2016268 A MEP2016268 A ME P2016268A ME 02557 B ME02557 B ME 02557B
Authority
ME
Montenegro
Prior art keywords
fused bicyclic
cetp inhibitor
bicyclic oxazolidinone
oxazolidinone cetp
inhibitor
Prior art date
Application number
MEP-2016-268A
Other languages
German (de)
English (en)
French (fr)
Inventor
Pengcheng Patrick Shao
Feng Ye
Petr Vachal
Deyou Sha
Revathi Reddy Katipally
Jian Liu
Wanying Sun
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ME02557B publication Critical patent/ME02557B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
MEP-2016-268A 2011-10-28 2012-10-25 Fuzionisani biciklicni oksazoliidinon kao inhibitor cetp ME02557B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552592P 2011-10-28 2011-10-28
EP12781551.2A EP2771345B1 (en) 2011-10-28 2012-10-25 Fused bicyclic oxazolidinone cetp inhibitor
PCT/US2012/061842 WO2013063217A1 (en) 2011-10-28 2012-10-25 Fused bicyclic oxazolidinone cetp inhibitor

Publications (1)

Publication Number Publication Date
ME02557B true ME02557B (me) 2017-02-20

Family

ID=47143312

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-268A ME02557B (me) 2011-10-28 2012-10-25 Fuzionisani biciklicni oksazoliidinon kao inhibitor cetp

Country Status (41)

Country Link
US (2) US8871738B2 (me)
EP (1) EP2771345B1 (me)
JP (1) JP5658427B2 (me)
KR (1) KR101686308B1 (me)
CN (1) CN103958524B (me)
AR (1) AR088565A1 (me)
AU (1) AU2012328759B2 (me)
BR (1) BR112014010204A2 (me)
CA (1) CA2852743C (me)
CL (1) CL2014001090A1 (me)
CO (1) CO6940419A2 (me)
CR (1) CR20140256A (me)
CY (1) CY1118464T1 (me)
DK (1) DK2771345T3 (me)
DO (1) DOP2014000086A (me)
EA (1) EA026123B1 (me)
EC (1) ECSP14002458A (me)
ES (1) ES2604953T3 (me)
GE (1) GEP20166434B (me)
HK (1) HK1195558A1 (me)
HR (1) HRP20161541T1 (me)
HU (1) HUE030568T2 (me)
IL (1) IL232130A (me)
IN (1) IN2014CN03073A (me)
JO (1) JO3210B1 (me)
LT (1) LT2771345T (me)
MA (1) MA35643B1 (me)
ME (1) ME02557B (me)
MX (1) MX345222B (me)
NI (1) NI201400034A (me)
PE (1) PE20141230A1 (me)
PL (1) PL2771345T3 (me)
PT (1) PT2771345T (me)
RS (1) RS55420B1 (me)
SG (1) SG11201401884PA (me)
SI (1) SI2771345T1 (me)
TN (1) TN2014000158A1 (me)
TW (1) TWI601731B (me)
UA (1) UA114612C2 (me)
WO (1) WO2013063217A1 (me)
ZA (2) ZA201403091B (me)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
CN103269592B (zh) 2010-10-29 2016-05-11 默沙东公司 环胺取代的噁唑烷酮cetp抑制剂
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US9717714B2 (en) 2012-12-19 2017-08-01 Merck Sharp & Dohme Corp. Spirocyclic CETP inhibitors
US9376408B2 (en) 2012-12-20 2016-06-28 Merck Sharp & Dohme Corp. Therapeutic thiazolidinone compounds
EP2943474B1 (en) * 2013-01-31 2017-07-05 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
US9981970B2 (en) 2013-07-30 2018-05-29 Merck Sharp & Dohme Corp. Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors
WO2015031228A1 (en) * 2013-08-30 2015-03-05 Merck Sharp & Dohme Corp. Oral pharmaceutical formulation of omarigliptin
US9688630B2 (en) 2013-10-10 2017-06-27 Merck Sharp & Dohme Corp. 3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein
WO2015094932A1 (en) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein
UA120922C2 (uk) 2014-02-05 2020-03-10 Дезима Фарма Б.В. Інгібітор білка-переносника ефіру холестерину (cetp) і фармацевтичні композиції, які містять вказаний інгібітор, для застосування в лікуванні або запобіганні серцево-судинним захворюванням
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
JP6980385B2 (ja) 2014-03-26 2021-12-15 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited Fgfr阻害剤とigf1r阻害剤の組合せ
WO2016018729A1 (en) 2014-07-29 2016-02-04 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
WO2016067194A1 (en) * 2014-10-27 2016-05-06 Sun Pharmaceutical Industries Limited Process for the preparation of anacetrapib and an intermediate thereof
KR20170087880A (ko) * 2014-11-28 2017-07-31 코와 가부시키가이샤 의약
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2016201310A1 (en) * 2015-06-12 2016-12-15 Rhodia Operations Hybrid nanoparticles containing dendrons, methods of producing such hybrid nanoparticles, and uses thereof
EP3322420B1 (en) 2015-07-13 2021-12-29 Merck Sharp & Dohme Corp. Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
KR20180052631A (ko) 2015-09-23 2018-05-18 얀센 파마슈티카 엔.브이. 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
CN106432053A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种尼拉帕布中间体4‑(3s‑哌啶‑3‑基)溴苯的制备方法
CN106432058A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种Niraparib中间体4‑(3S‑哌啶‑3‑基)苯胺的制备方法
CN111285894B (zh) * 2018-12-10 2021-03-05 北京天一绿甫医药科技有限公司 用于制备软海绵素类化合物的中间体及其制备方法
CN110639018B (zh) * 2019-11-14 2020-06-26 牡丹江医学院 一种防治老年性高血压的药物组合物及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
ATE362468T1 (de) 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
EP1357908A4 (en) 2001-01-30 2009-07-15 Merck & Co Inc ACYL-SULFAMIDES FOR THE TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS
WO2003011824A1 (en) 2001-07-31 2003-02-13 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
ES2342596T3 (es) 2002-08-29 2010-07-09 MERCK SHARP & DOHME CORP. Indoles con actividad anti-diabetica.
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
US7319170B2 (en) 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives
JP2007501863A (ja) * 2003-06-12 2007-02-01 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
CA2533435A1 (en) 2003-08-13 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
CN1938320A (zh) * 2004-03-26 2007-03-28 伊莱利利公司 用于治疗异常脂肪血症的化合物和方法
JP2007530550A (ja) 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
EP1737811B1 (en) * 2004-04-13 2016-08-10 Merck Sharp & Dohme Corp. Cetp inhibitors
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
CN101384590A (zh) * 2005-12-22 2009-03-11 先灵公司 作为凝血酶受体拮抗剂的唑并异喹啉
CA2635010A1 (en) 2005-12-30 2007-07-19 Amjad Ali Oxazolidinone derivatives as cetp inhibitors
US7910592B2 (en) 2005-12-30 2011-03-22 Merck Sharp & Dohme Corp. CETP inhibitors
US7915271B2 (en) 2005-12-30 2011-03-29 Merck Sharp & Dohme Corp. 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
EP2348859B1 (en) * 2008-10-01 2013-12-04 Merck Sharp & Dohme Corp. Prodrugs of oxazolidinone cetp inhibitors
WO2011028395A1 (en) 2009-08-24 2011-03-10 Merck Sharp & Dohme Corp. Pyridyl oxazolidinone cetp inhibitor
CN103269592B (zh) 2010-10-29 2016-05-11 默沙东公司 环胺取代的噁唑烷酮cetp抑制剂
EP2844252B1 (en) 2012-05-02 2016-11-30 Merck Sharp & Dohme Corp. Cyclic amine substituted heterocyclic compounds as cetp inhibitors

Also Published As

Publication number Publication date
MA35643B1 (fr) 2014-11-01
JP5658427B2 (ja) 2015-01-28
NZ625435A (en) 2015-12-24
AR088565A1 (es) 2014-06-18
JP2014532652A (ja) 2014-12-08
IL232130A (en) 2017-07-31
HUE030568T2 (en) 2017-05-29
EP2771345A1 (en) 2014-09-03
LT2771345T (lt) 2016-11-25
IL232130A0 (en) 2014-05-28
CN103958524A (zh) 2014-07-30
US20140378493A1 (en) 2014-12-25
HRP20161541T1 (hr) 2016-12-30
ZA201406833B (en) 2016-02-24
AU2012328759B2 (en) 2015-09-10
ZA201403091B (en) 2015-04-29
ECSP14002458A (es) 2015-11-30
PT2771345T (pt) 2016-11-30
MX2014005074A (es) 2014-08-01
CL2014001090A1 (es) 2014-08-01
KR20140094571A (ko) 2014-07-30
EP2771345B1 (en) 2016-09-21
PE20141230A1 (es) 2014-09-28
US8871738B2 (en) 2014-10-28
TN2014000158A1 (en) 2015-09-30
US9346825B2 (en) 2016-05-24
SI2771345T1 (sl) 2016-12-30
ES2604953T3 (es) 2017-03-10
IN2014CN03073A (me) 2015-07-31
AU2012328759A1 (en) 2014-05-01
CA2852743A1 (en) 2013-05-02
DK2771345T3 (en) 2017-01-09
US20130109649A1 (en) 2013-05-02
JO3210B1 (ar) 2018-03-08
GEP20166434B (en) 2016-02-10
DOP2014000086A (es) 2014-07-15
CY1118464T1 (el) 2017-07-12
TW201321388A (zh) 2013-06-01
CO6940419A2 (es) 2014-05-09
KR101686308B1 (ko) 2016-12-13
SG11201401884PA (en) 2014-09-26
CN103958524B (zh) 2016-04-06
BR112014010204A2 (pt) 2017-05-09
UA114612C2 (uk) 2017-07-10
NI201400034A (es) 2014-10-10
EA201490889A1 (ru) 2015-05-29
RS55420B1 (sr) 2017-04-28
CR20140256A (es) 2014-07-15
PL2771345T3 (pl) 2017-04-28
EA026123B1 (ru) 2017-03-31
CA2852743C (en) 2016-08-02
HK1195558A1 (zh) 2014-11-14
TWI601731B (zh) 2017-10-11
WO2013063217A1 (en) 2013-05-02
MX345222B (es) 2017-01-20

Similar Documents

Publication Publication Date Title
ZA201406833B (en) Fused bicyclic oxazolidinone cetp inhibitor
HK1201268A1 (en) Bicyclic piperazine compounds
IL227252A0 (en) Aminodihydrothiazine history from sisterhood
GB201101140D0 (en) Fused aminodihydrothiazine derivatives
EP2717099A4 (en) TONER
EP2717100A4 (en) TONER
EP2710430A4 (en) INK POWDER
EP2710432A4 (en) TONER
EP2691815A4 (en) TONER
GB201200835D0 (en) Lenses
EP2710431A4 (en) TONER
EP2753982A4 (en) TONER
PL2771659T3 (pl) Termoelement
EP2745175A4 (en) TONER CONTAINER
PL2726238T3 (pl) Uchwyt zaciskowy
EP2727676A4 (en) TAPS HOLDER
IL233002A0 (en) New compounds for neural modulation
GB2494423B (en) Electrofusion fitting
EP2663515A4 (en) SPINDLE
GB2491976B (en) Adaptation lens
GB2492454B (en) Cleaning apparatuses for fusing systems
GB201406670D0 (en) Collar
PL120444U1 (pl) Trawersa
ZA201309684B (en) Holder
IL227821A0 (en) sections of cetp